Cargando…

Inhibition of Oxidative Stress and the NF-κB Pathway by a Vitamin E Derivative: Pharmacological Approach against Parkinson’s Disease

[Image: see text] Parkinson’s disease (PD) is a progressive neurodegenerative disorder. In this study, PD was induced via (ip) injection of haloperidol (1 mg/kg/day). Animals were divided into seven groups (n = 70). Group I received the vehicle carboxymethylcellulose (CMC; 0.5%), group II was treate...

Descripción completa

Detalles Bibliográficos
Autores principales: Iqbal, Afshan, Anwar, Fareeha, Saleem, Uzma, Khan, Saira Sami, Karim, Adnan, Ahmad, Bashir, Gul, Mubashra, Iqbal, Zafer, Ismail, Tariq
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2022
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9753179/
https://www.ncbi.nlm.nih.gov/pubmed/36530334
http://dx.doi.org/10.1021/acsomega.2c05500
_version_ 1784850908479225856
author Iqbal, Afshan
Anwar, Fareeha
Saleem, Uzma
Khan, Saira Sami
Karim, Adnan
Ahmad, Bashir
Gul, Mubashra
Iqbal, Zafer
Ismail, Tariq
author_facet Iqbal, Afshan
Anwar, Fareeha
Saleem, Uzma
Khan, Saira Sami
Karim, Adnan
Ahmad, Bashir
Gul, Mubashra
Iqbal, Zafer
Ismail, Tariq
author_sort Iqbal, Afshan
collection PubMed
description [Image: see text] Parkinson’s disease (PD) is a progressive neurodegenerative disorder. In this study, PD was induced via (ip) injection of haloperidol (1 mg/kg/day). Animals were divided into seven groups (n = 70). Group I received the vehicle carboxymethylcellulose (CMC; 0.5%), group II was treated with designated 1 mg/kg haloperidol, and group III received the standard drug Sinemet (100 mg/kg), while groups IV–VII received a tocopherol derivative (Toco-D) at dose levels of 5, 10, 20, and 40 mg/kg, respectively, via the oral route. All groups received haloperidol for 23 consecutive days after their treatments except the control group. The improvement in locomotor activity and motor coordination was evaluated by using behavioral tests. Oxidative stress markers, neurotransmitters, and monoamine oxidase B (MAO-B) as well as NF-κB levels in the whole brain were measured. mRNA expression analysis of α-synuclein was carried out using the PCR technique. Toco-D at 20 mg/kg showed the maximum improvement in locomotor activity. The levels of antioxidant enzymes and neurotransmitters were also increased by the treatment with Toco-D. Inflammatory cytokine levels and mRNA expression of α-synuclein were decreased by Toco-D in treated animals. This study concluded that Toco-D might be effective in the improvement of locomotor activity and motor coordination in haloperidol-induced PD.
format Online
Article
Text
id pubmed-9753179
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher American Chemical Society
record_format MEDLINE/PubMed
spelling pubmed-97531792022-12-16 Inhibition of Oxidative Stress and the NF-κB Pathway by a Vitamin E Derivative: Pharmacological Approach against Parkinson’s Disease Iqbal, Afshan Anwar, Fareeha Saleem, Uzma Khan, Saira Sami Karim, Adnan Ahmad, Bashir Gul, Mubashra Iqbal, Zafer Ismail, Tariq ACS Omega [Image: see text] Parkinson’s disease (PD) is a progressive neurodegenerative disorder. In this study, PD was induced via (ip) injection of haloperidol (1 mg/kg/day). Animals were divided into seven groups (n = 70). Group I received the vehicle carboxymethylcellulose (CMC; 0.5%), group II was treated with designated 1 mg/kg haloperidol, and group III received the standard drug Sinemet (100 mg/kg), while groups IV–VII received a tocopherol derivative (Toco-D) at dose levels of 5, 10, 20, and 40 mg/kg, respectively, via the oral route. All groups received haloperidol for 23 consecutive days after their treatments except the control group. The improvement in locomotor activity and motor coordination was evaluated by using behavioral tests. Oxidative stress markers, neurotransmitters, and monoamine oxidase B (MAO-B) as well as NF-κB levels in the whole brain were measured. mRNA expression analysis of α-synuclein was carried out using the PCR technique. Toco-D at 20 mg/kg showed the maximum improvement in locomotor activity. The levels of antioxidant enzymes and neurotransmitters were also increased by the treatment with Toco-D. Inflammatory cytokine levels and mRNA expression of α-synuclein were decreased by Toco-D in treated animals. This study concluded that Toco-D might be effective in the improvement of locomotor activity and motor coordination in haloperidol-induced PD. American Chemical Society 2022-12-02 /pmc/articles/PMC9753179/ /pubmed/36530334 http://dx.doi.org/10.1021/acsomega.2c05500 Text en © 2022 The Authors. Published by American Chemical Society https://creativecommons.org/licenses/by-nc-nd/4.0/Permits non-commercial access and re-use, provided that author attribution and integrity are maintained; but does not permit creation of adaptations or other derivative works (https://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Iqbal, Afshan
Anwar, Fareeha
Saleem, Uzma
Khan, Saira Sami
Karim, Adnan
Ahmad, Bashir
Gul, Mubashra
Iqbal, Zafer
Ismail, Tariq
Inhibition of Oxidative Stress and the NF-κB Pathway by a Vitamin E Derivative: Pharmacological Approach against Parkinson’s Disease
title Inhibition of Oxidative Stress and the NF-κB Pathway by a Vitamin E Derivative: Pharmacological Approach against Parkinson’s Disease
title_full Inhibition of Oxidative Stress and the NF-κB Pathway by a Vitamin E Derivative: Pharmacological Approach against Parkinson’s Disease
title_fullStr Inhibition of Oxidative Stress and the NF-κB Pathway by a Vitamin E Derivative: Pharmacological Approach against Parkinson’s Disease
title_full_unstemmed Inhibition of Oxidative Stress and the NF-κB Pathway by a Vitamin E Derivative: Pharmacological Approach against Parkinson’s Disease
title_short Inhibition of Oxidative Stress and the NF-κB Pathway by a Vitamin E Derivative: Pharmacological Approach against Parkinson’s Disease
title_sort inhibition of oxidative stress and the nf-κb pathway by a vitamin e derivative: pharmacological approach against parkinson’s disease
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9753179/
https://www.ncbi.nlm.nih.gov/pubmed/36530334
http://dx.doi.org/10.1021/acsomega.2c05500
work_keys_str_mv AT iqbalafshan inhibitionofoxidativestressandthenfkbpathwaybyavitaminederivativepharmacologicalapproachagainstparkinsonsdisease
AT anwarfareeha inhibitionofoxidativestressandthenfkbpathwaybyavitaminederivativepharmacologicalapproachagainstparkinsonsdisease
AT saleemuzma inhibitionofoxidativestressandthenfkbpathwaybyavitaminederivativepharmacologicalapproachagainstparkinsonsdisease
AT khansairasami inhibitionofoxidativestressandthenfkbpathwaybyavitaminederivativepharmacologicalapproachagainstparkinsonsdisease
AT karimadnan inhibitionofoxidativestressandthenfkbpathwaybyavitaminederivativepharmacologicalapproachagainstparkinsonsdisease
AT ahmadbashir inhibitionofoxidativestressandthenfkbpathwaybyavitaminederivativepharmacologicalapproachagainstparkinsonsdisease
AT gulmubashra inhibitionofoxidativestressandthenfkbpathwaybyavitaminederivativepharmacologicalapproachagainstparkinsonsdisease
AT iqbalzafer inhibitionofoxidativestressandthenfkbpathwaybyavitaminederivativepharmacologicalapproachagainstparkinsonsdisease
AT ismailtariq inhibitionofoxidativestressandthenfkbpathwaybyavitaminederivativepharmacologicalapproachagainstparkinsonsdisease